Please login to the form below

Not currently logged in
Email:
Password:

eye disease

This page shows the latest eye disease news and features for those working in and with pharma, biotech and healthcare.

Europe responding to gene therapy challenge, but picture remains fragmented

Europe responding to gene therapy challenge, but picture remains fragmented

Last year saw the launch of three groundbreaking products in Europe: the CAR-T competitors, Kymriah from Novartis and Gilead’s Yescarta and Spark’s rare eye disease gene therapy Luxturna. ... Giorgio Iotti, head of programme leadership and control,

Latest news

  • Takeda sells blockbuster-in-waiting Xiirda to Novartis for $5.3bn Takeda sells blockbuster-in-waiting Xiirda to Novartis for $5.3bn

    The drug was acquired in its recent buyout of Xiidra’s maker Shire, while a leaner Novartis hopes to strengthen its prescription medicine eye disease portfolio after spinning off consumer health ... These drugs saw its eye-disease portfolio drop 1% in

  • Gyroscope advances gene therapy platform, merges with Orbit Gyroscope advances gene therapy platform, merges with Orbit

    The announcement comes hot on the heels of news of another two biotechs Histogenics and Ocugen merging to become one specialist eye disease company. ... Both Ocugen and Histogenics are US-based, and the companies are hoping the merge will further

  • Alnylam swaps Sanofi for Regeneron as R&D partner Alnylam swaps Sanofi for Regeneron as R&D partner

    Novel alliance between two biotechs. Regeneron has agreed to pay $800m to gene-silencing specialist Alnylam to buy into its pipeline of drugs for central nervous system, eye and liver diseases. ... Regeneron will however take the lead on eye disease

  • Horizon sunny as thyroid eye disease drug hits the mark Horizon sunny as thyroid eye disease drug hits the mark

    New treatment helps lessen eye bulging. Horizon Pharma shares rose strongly after it reported a positive phase 3 trial of teprotumumab for the treatment of active thyroid eye disease (TED), which ... If approved, teprotumumab would give physicians the

  • Ipsen buys rare disease group Clementia in $1.3bn deal Ipsen buys rare disease group Clementia in $1.3bn deal

    Will acquire lead multiple rare disease candidate palovarotene. Ipsen is set to pay out a total of $1.3bn to buy Clementia Pharmaceuticals in a move that will significantly boost its ... Alongside its potential in FOP and MO, for which palovarotene has

More from news
Approximately 6 fully matching, plus 49 partially matching documents found.

Latest Intelligence

  • Pharma deals during March 2013 Pharma deals during March 2013

    However, ophthalmology is increasingly an area of interest in the industry with potential for growth as the global population ages; it is estimated that around 25m people have dry eye disease ... 175. SARcode Bioscience/ Shire. Acquisition. SAR 1118 for

  • Interview: Joseph Jimenez, Novartis Interview: Joseph Jimenez, Novartis

    There is a growing demand for eye care, owing to the rising prevalence of eye disease, an ageing global population and increased demand for healthcare in emerging markets. ... This is demonstrated by the fact that rare disease research is central to its

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

  • 'Fake news': battling misinformation in healthcare

    The article is entitled ‘Alzheimer’s disease can be spotted through simple eye test’ and whilst this article is based on  genuine research, it is  far too early to be making ... As a result, the public was misinformed about a very serious and

  • emotive adds to medical team with new Scientific Lead and Associate Medical Writer

    Kate is experienced in a wide range of therapy areas, including immunology, specifically Crohn’s disease, ulcerative colitis and psoriatic arthritis, in ophthalmology, including retinal diseases, glaucoma and dry eye disease, ... emotive is an

  • The power of observation in gathering patient insights

    For example, we recently conducted a multi-country research project for a rare eye disease. ... Patients walked us around their homes; sharing with us stories about life before and after their disease, adding significant layers of insight to the findings

  • PAN trio run for charity

    RP is an inherited disease of the eye, where the light sensitive cells of the retina cease to function and die away. ... However, the research being undertaken at Moorfields Eye Hospital hopes to slow or even reverse this disease by injecting cells from

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

The Exhibition Hall: Past, Present and Future
As I sit here at another pharma conference, I start to reflect on how they have changed over the years....
Success breeds success
This week we received the exciting news that we have been shortlisted for the Times Business Awards 2019, Tunbridge Wells in the 'Best Business 1-25 Employees' category....
Turning learning into action: The challenge of behaviour change
...

Infographics